🔗 Share this article

Elected officials have raised concerns that the United Kingdom's negotiated accords with Washington are "fundamentally unstable." This stems from revelations that a recently announced deal on medicines, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond limited headline terms published in government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, hailed as a "generational" achievement, exists as an "statement of intent" without formal ratification. It has been highlighted that the press releases from the UK and US governments present the deal in sharply different terms. The British version focuses on securing "zero per cent tariffs" as a singular success, while the American announcement highlights the agreement for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for little more than a verbal promise from President Trump," commented David Henig, a trade expert. "It is documented he has form for not honouring his word."

A Pattern of Unreliability

Anxieties have been heightened by Washington's recent decision to put on ice the high-value digital accord, which was previously described as "a transformative pact" in the bilateral relationship. The US claimed a insufficient movement from the UK on lowering trade barriers as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an initial accord have not been formally approved by the US, despite a fast-approaching January deadline. "Our understanding is that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Behind the scenes, ministers have voiced worries that the government's deals with Washington are unstable and unpredictable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another framed the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, remarked: "Perhaps most shocking than the administration's tactics is the UK government's naive belief that his administration is a reliable partner. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Government figures have attempted to minimize the chances of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, wanting clarity on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that unpredictability is a feature of dealing with the current US leadership. However, they contend that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a solid gain," one official said.

Yet, problems have arisen in carrying out the May tariff agreement. Promised reciprocal agricultural allowances have not materialized, and the pledge to "eliminate duties on UK metals" has not been fulfilled, with tariffs staying at 25%.

Moving forward, the two sides have agreed to resume talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.